Osr Holdings Inc (OSRH)

$0.36 -0.01 (-2.22%)
Market Cap 13.75M
Revenue (ttm) 2.91M
Net Income (ttm) -27.06M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -929.90%
Debt to Equity Ratio 0.04
Volume 320,882
Avg Vol 7,733,460
Day's Range N/A - N/A
Shares Out 35.11M
Stochastic %K 3%
Beta 0.61
Analysts Strong Buy
Price Target N/A

Company Profile

OSR Health, Inc., a healthcare holding company, develops a portfolio of therapies and healthcare solutions in the United States, Europe, and Korea. The company develops immunotherapy products, including VXM01, an immuno-oncology candidate for glioblastoma completed phase 2 clinical trial, as well as preclinical stage products, such as VXM04 to treat mesothelin; VXM06 for the treatment of Wilms Tumor Protein (WT1); VXM08 for Carcinoembryonic antigen (CEA); and VXM10 for PD-L1. It is also developi...

Industry: Biotechnology
Sector: Healthcare
Phone: 425 635 7700
Address:
10900 NE 4th Street, Suite 2300, Bellevue, United States
CelestialSurfing
CelestialSurfing Jul. 4 at 8:00 PM
$OSRH I’m still not fully convinced on this one. I put a good chunk of my portfolio into another stock I follow because new management turned around the company and put their money where their mouth is with: 1.) Affiliated partner renting out their datacenters, with compensation being way OTM warrants. (Reminds me of BCME deal) 2.) Open market insider purchases from ceo, board, and partners It’s interesting to me that there are zero open market purchases by insiders on OSRH. If this CVR deal is so legitimate? Why aren’t they loading up? Their ~400k salaries surely have room for some purchases
2 · Reply
Spiderman1979
Spiderman1979 Jul. 4 at 1:32 PM
$OSRH pretty darn, good news! Right now, I will take it.
1 · Reply
rodyar
rodyar Jul. 4 at 12:47 PM
$OSRH I hope the snowball is just about ready to start rolling down the mountain this month
1 · Reply
HarmonicHaven
HarmonicHaven Jul. 3 at 9:37 PM
$OSRH got fresh third-party coverage after Emerging Growth Research reaffirmed a Buy-Emerging rating and $10 PT. New visibility matters here — especially for a small-cap healthcare name that can move on coverage alone.
1 · Reply
GoldenGateGamma
GoldenGateGamma Jul. 3 at 9:22 PM
$OSRH got fresh third-party coverage after Emerging Growth Research reaffirmed a Buy-Emerging rating and $10 PT. New visibility matters here — especially for a small-cap healthcare name that can move on coverage alone.
0 · Reply
rodyar
rodyar Jul. 3 at 3:50 PM
$OSRH risk versus reward. Nobody ever knows exactly what a stock is going to do so when you go in and buy it, you weigh the potential versus risking everything. With the CVR on the table that makes it worth the risk in my opinion for new investors. Obviously the company feels pretty confident what they’re going to do over the next year and by this time next year, we will either be really happy or not so happy.
1 · Reply
Panda0820
Panda0820 Jul. 3 at 3:31 PM
$OSRH Adding and Adding
2 · Reply
Safey_8
Safey_8 Jul. 3 at 3:12 PM
$OSRH still
0 · Reply
KeepItRealistic
KeepItRealistic Jul. 3 at 2:08 PM
$OSRH what is stopping BCME investors from buying up a good chunk of the remaining float here estimated at around 20m ? A shareholder loyalty program 🤷🏻‍♂️ Who needs these retarded fliptards when we have BCME ! Smart loyal shareholders will just ride on BCME’s coattails ! I am excited to that possibility
1 · Reply
KeepItRealistic
KeepItRealistic Jul. 3 at 3:04 AM
$OSRH to new long investors buy 10k shares and HOLD for 1 year and turn 10k shares to 60k shares. • Details: One non-transferable CVR per share held as of the record date (targeted for July 31, 2026). Subject to legal counsel approval. • Tiered Rewards: The tiered reward structure only has to be at or above the specified price level on the 3, 6, 9, or 12 month observation date • ≥ $2.00 for 3 months → 0.5 additional shares • ≥ $3.00 for 6 months → 1.0 additional shares • ≥ $4.00 for 9 months → 1.5 additional shares • ≥ $5.00 for 12 months → 2.0 additional shares • Maximum upside: A shareholder holding through all tiers could receive 5 additional shares per original share, effectively turning 1 share into 6.
0 · Reply
Latest News on OSRH
Emerging Growth Research Issues Flash Report on OSR Health, Inc., Reaffirms Buy-Emerging Rating and $10.00 Price Target

Jul 2, 2026, 9:00 AM EDT - 2 days ago

Emerging Growth Research Issues Flash Report on OSR Health, Inc., Reaffirms Buy-Emerging Rating and $10.00 Price Target

OSR Health Announces Shareholder Loyalty Program to Reward Conviction Holders With Additional Shares

Jun 25, 2026, 8:32 AM EDT - 9 days ago

OSR Health Announces Shareholder Loyalty Program to Reward Conviction Holders With Additional Shares

OSR Holdings changes corporate name to OSR Health

2026-06-22T13:28:55.000Z - 12 days ago

OSR Holdings changes corporate name to OSR Health

OSR Holdings Is Now OSR Health - A New Name That Says Exactly What We Do

Jun 22, 2026, 9:06 AM EDT - 12 days ago

OSR Holdings Is Now OSR Health - A New Name That Says Exactly What We Do

CEO Statement to Shareholders

Jun 3, 2026, 12:05 PM EDT - 4 weeks ago

CEO Statement to Shareholders

OSR Holdings acquires full VXM01 intellectual property portfolio for $30M

2026-05-27T15:40:49.000Z - 5 weeks ago

OSR Holdings acquires full VXM01 intellectual property portfolio for $30M

OSR Holdings Acquires Full VXM01 Intellectual Property Portfolio in $30 Million Transaction

May 27, 2026, 9:06 AM EDT - 5 weeks ago

OSR Holdings Acquires Full VXM01 Intellectual Property Portfolio in $30 Million Transaction

OSR Holdings CEO says company not pursuing reverse stock split

2026-05-12T19:35:00.000Z - 7 weeks ago

OSR Holdings CEO says company not pursuing reverse stock split

Emerging Growth Research Issues Flash Report on OSR Holdings, Reaffirms Buy-Emerging Rating and $10.00 Price Target

May 5, 2026, 1:05 PM EDT - 2 months ago

Emerging Growth Research Issues Flash Report on OSR Holdings, Reaffirms Buy-Emerging Rating and $10.00 Price Target

OSR Holdings to Present VXM01 Licensing Agreement at Emerging Growth Conference May 7, 2026

Apr 30, 2026, 9:15 AM EDT - 2 months ago

OSR Holdings to Present VXM01 Licensing Agreement at Emerging Growth Conference May 7, 2026

OSR Holdings enters $815M global license agreement for VXM01 with BCM Europe

2026-04-29T16:28:46.000Z - 2 months ago

OSR Holdings enters $815M global license agreement for VXM01 with BCM Europe

OSR Holdings Executes Definitive $815 Million Global License Agreement for VXM01 with BCM Europe

Apr 29, 2026, 9:50 AM EDT - 2 months ago

OSR Holdings Executes Definitive $815 Million Global License Agreement for VXM01 with BCM Europe

OSR Holdings eliminates $2.02M warrant overhang

2026-04-09T13:34:34.000Z - 3 months ago

OSR Holdings eliminates $2.02M warrant overhang

OSR Holdings Eliminates $2.02 Million Warrant Overhang with Premium-Priced Convertible Note

Apr 9, 2026, 9:15 AM EDT - 3 months ago

OSR Holdings Eliminates $2.02 Million Warrant Overhang with Premium-Priced Convertible Note

OSR Holdings to Update Investors at the Emerging Growth Conference on April 1, 2026

Mar 30, 2026, 9:00 AM EDT - 3 months ago

OSR Holdings to Update Investors at the Emerging Growth Conference on April 1, 2026

Emerging Growth Research Issues Flash Report on OSR Holdings, Inc., Reaffirms Buy-Emerging Rating and $10.00 Price Target

Mar 27, 2026, 9:00 AM EDT - 3 months ago

Emerging Growth Research Issues Flash Report on OSR Holdings, Inc., Reaffirms Buy-Emerging Rating and $10.00 Price Target

OSR Holdings announces update to $815M VXM01 licensing deal structure

2026-03-23T12:46:05.000Z - 3 months ago

OSR Holdings announces update to $815M VXM01 licensing deal structure

OSR Holdings Updates $815 Million VXM01 Licensing Deal Structure to Capture Value at Parent Level

Mar 23, 2026, 8:30 AM EDT - 3 months ago

OSR Holdings Updates $815 Million VXM01 Licensing Deal Structure to Capture Value at Parent Level

OSR Holdings subsidiary signs NDA with Sinopharm

2026-03-19T13:07:19.000Z - 3 months ago

OSR Holdings subsidiary signs NDA with Sinopharm

OSR Holdings subsidiary signs NDA with Sinopharm

2026-03-19T13:07:07.000Z - 3 months ago

OSR Holdings subsidiary signs NDA with Sinopharm

Woori IO, an OSR Company, Signs NDA with Sinopharm to Explore China Commercial Opportunities

Mar 19, 2026, 8:55 AM EDT - 3 months ago

Woori IO, an OSR Company, Signs NDA with Sinopharm to Explore China Commercial Opportunities

OSR Holdings granted 180-day Nasdaq extension

2026-03-05T14:44:08.000Z - 4 months ago

OSR Holdings granted 180-day Nasdaq extension

OSR Holdings, Inc. Granted 180-Day Nasdaq Extension; Reaffirms Strategic Momentum

Mar 5, 2026, 9:30 AM EST - 4 months ago

OSR Holdings, Inc. Granted 180-Day Nasdaq Extension; Reaffirms Strategic Momentum

OSR Holdings completes Woori IO acquisition

2026-01-27T13:50:45.000Z - 5 months ago

OSR Holdings completes Woori IO acquisition

OSR Holdings Completes Woori IO Acquisition, Secures Long-Term Shareholder Alignment, and Reviews Strategic Combination of Medical Device Subsidiaries

Jan 27, 2026, 8:30 AM EST - 5 months ago

OSR Holdings Completes Woori IO Acquisition, Secures Long-Term Shareholder Alignment, and Reviews Strategic Combination of Medical Device Subsidiaries

Woori IO, an OSR Company, Highlights FDA Clarification on Non-Medical Wearables as a Catalyst for Accelerated Commercial Launch

Jan 22, 2026, 9:55 AM EST - 5 months ago

Woori IO, an OSR Company, Highlights FDA Clarification on Non-Medical Wearables as a Catalyst for Accelerated Commercial Launch

Vaximm Appoints Sébastien Wieckowski, PhD, as Chief Scientific Officer to Advance Next-Generation Oral Immunotherapy Platform

Jan 16, 2026, 9:20 AM EST - 6 months ago

Vaximm Appoints Sébastien Wieckowski, PhD, as Chief Scientific Officer to Advance Next-Generation Oral Immunotherapy Platform

Vaximm, an OSR Company, Receives Binding Term Sheet from BCM Europe for Global Exclusive License of VXM01 with $30M Upfront and Up to $815M in Milestones

Jan 12, 2026, 8:05 AM EST - 6 months ago

Vaximm, an OSR Company, Receives Binding Term Sheet from BCM Europe for Global Exclusive License of VXM01 with $30M Upfront and Up to $815M in Milestones

OSR Holdings announces Woori IO shareholders approve share exchange

2025-12-19T16:55:10.000Z - 7 months ago

OSR Holdings announces Woori IO shareholders approve share exchange

Woori IO Shareholders Approve Share Exchange to Become Wholly-Owned Subsidiary of OSR Holdings

Dec 19, 2025, 11:50 AM EST - 7 months ago

Woori IO Shareholders Approve Share Exchange to Become Wholly-Owned Subsidiary of OSR Holdings

Emerging Growth Research Issues Flash Report on OSR Holdings, Inc., Reaffirms Buy-Emerging Rating and $10.00 Price Target Following Major Licensing Agreement

Dec 4, 2025, 3:19 PM EST - 7 months ago

Emerging Growth Research Issues Flash Report on OSR Holdings, Inc., Reaffirms Buy-Emerging Rating and $10.00 Price Target Following Major Licensing Agreement

Vaximm updates term sheet with BCM Europe to shorten exclusivity period

2025-12-02T15:06:23.000Z - 7 months ago

Vaximm updates term sheet with BCM Europe to shorten exclusivity period

Vaximm AG, an OSR Company, Updates Term Sheet with BCM Europe to Shorten Exclusivity Period to Three Months

Dec 2, 2025, 9:53 AM EST - 7 months ago

Vaximm AG, an OSR Company, Updates Term Sheet with BCM Europe to Shorten Exclusivity Period to Three Months

OSR Holdings to Present at the Emerging Growth Conference on December 10, 2025

Dec 1, 2025, 3:01 PM EST - 7 months ago

OSR Holdings to Present at the Emerging Growth Conference on December 10, 2025

OSR Holdings’ Vaximm AG enters non-binding term sheet with BCM Europe

2025-11-21T14:25:17.000Z - 8 months ago

OSR Holdings’ Vaximm AG enters non-binding term sheet with BCM Europe

Vaximm AG, an OSR Company, Enters Term Sheet With BCM Europe for Potential VXM01 License with $20M Upfront and Up to $815M in Milestones

Nov 21, 2025, 9:20 AM EST - 8 months ago

Vaximm AG, an OSR Company, Enters Term Sheet With BCM Europe for Potential VXM01 License with $20M Upfront and Up to $815M in Milestones

OSR Holdings Appoints Scientific Co-Founder Dr. Andreas Niethammer as Chief Executive Officer of Vaximm AG to Lead Next Phase of Immuno-Oncology Expansion

Nov 14, 2025, 11:10 AM EST - 8 months ago

OSR Holdings Appoints Scientific Co-Founder Dr. Andreas Niethammer as Chief Executive Officer of Vaximm AG to Lead Next Phase of Immuno-Oncology Expansion

OSR Holdings’ glucose monitor demonstrates accuracy and precision in pilot study

2025-11-06T13:48:10.000Z - 8 months ago

OSR Holdings’ glucose monitor demonstrates accuracy and precision in pilot study

OSR Holdings Announces Woori IO's Noninvasive Glucose Monitor Demonstrates High Accuracy and Precision in Company-Sponsored Pilot Study

Nov 6, 2025, 8:30 AM EST - 8 months ago

OSR Holdings Announces Woori IO's Noninvasive Glucose Monitor Demonstrates High Accuracy and Precision in Company-Sponsored Pilot Study

Emerging Growth Research Initiates Coverage on OSR Holdings, Inc. with a Buy-Emerging Rating and $10.00 Price Target

Oct 20, 2025, 11:39 AM EDT - 9 months ago

Emerging Growth Research Initiates Coverage on OSR Holdings, Inc. with a Buy-Emerging Rating and $10.00 Price Target

OSR Holdings to acquire Woori IO for needle-free glucose monitoring

2025-10-14T12:41:26.000Z - 9 months ago

OSR Holdings to acquire Woori IO for needle-free glucose monitoring

OSR Holdings Signs Definitive Agreement to Acquire Woori IO, a Pioneer in Noninvasive Glucose Monitoring with Potential to Transform Diabetes Care

Oct 14, 2025, 8:30 AM EDT - 9 months ago

OSR Holdings Signs Definitive Agreement to Acquire Woori IO, a Pioneer in Noninvasive Glucose Monitoring with Potential to Transform Diabetes Care

OSR Holdings receives non-compliance letter from Nasdaq

2025-09-09T21:35:11.000Z - 10 months ago

OSR Holdings receives non-compliance letter from Nasdaq

OSR Holdings Receives Nasdaq Minimum Bid Price Deficiency Notice; Company Highlights Unusual Trading Activity

Sep 9, 2025, 5:30 PM EDT - 10 months ago

OSR Holdings Receives Nasdaq Minimum Bid Price Deficiency Notice; Company Highlights Unusual Trading Activity

OSR Holdings to Host Virtual Investor Event Providing Key Corporate Updates and Strategic Direction on August 6, 2025

Aug 1, 2025, 1:29 PM EDT - 1 year ago

OSR Holdings to Host Virtual Investor Event Providing Key Corporate Updates and Strategic Direction on August 6, 2025

OSR Holdings Provides Transparency Update on Equity Financing Instruments

Jul 31, 2025, 12:45 PM EDT - 1 year ago

OSR Holdings Provides Transparency Update on Equity Financing Instruments

OSR Holdings Provides Strategic Update on Woori IO Term Sheet and Share Exchange Structure

Jul 30, 2025, 4:10 PM EDT - 1 year ago

OSR Holdings Provides Strategic Update on Woori IO Term Sheet and Share Exchange Structure

OSR Holdings to acquire glucose monitoring provider Woori IO

2025-07-24T11:41:06.000Z - 1 year ago

OSR Holdings to acquire glucose monitoring provider Woori IO

OSR Holdings Enters into Term Sheet to Acquire Woori IO, a Pioneer in Noninvasive Glucose Monitoring Technology

Jul 24, 2025, 7:30 AM EDT - 1 year ago

OSR Holdings Enters into Term Sheet to Acquire Woori IO, a Pioneer in Noninvasive Glucose Monitoring Technology

OSR Holdings Appoints Dr. Andreas Niethammer as Chief Medical Officer of Vaximm AG, an OSR Company

Jul 15, 2025, 7:30 AM EDT - 1 year ago

OSR Holdings Appoints Dr. Andreas Niethammer as Chief Medical Officer of Vaximm AG, an OSR Company

OSR Holdings Announces Strategic Roadmap for Tokenization Under Reg D Framework in Partnership with BCM Europe AG

Jul 9, 2025, 7:58 AM EDT - 1 year ago

OSR Holdings Announces Strategic Roadmap for Tokenization Under Reg D Framework in Partnership with BCM Europe AG

OSR Holdings, BCM Europe, and Taekwondo Cooperative Announce Strategic MOU to Launch Blockchain-Based OSRH Token

May 22, 2025, 7:36 AM EDT - 1 year ago

OSR Holdings, BCM Europe, and Taekwondo Cooperative Announce Strategic MOU to Launch Blockchain-Based OSRH Token

Darnatein to Present at 14th International BMP Conference Highlighting Advances in Regenerative Biologics

May 2, 2025, 7:30 AM EDT - 1 year ago

Darnatein to Present at 14th International BMP Conference Highlighting Advances in Regenerative Biologics

Darnatein, an OSR Company, Broadens Intellectual Property Protection for Innovative Osteoarthritis Treatment Technology

Apr 9, 2025, 7:54 AM EDT - 1 year ago

Darnatein, an OSR Company, Broadens Intellectual Property Protection for Innovative Osteoarthritis Treatment Technology

OSR Holdings, Inc. (NASDAQ: OSRH) Enters Into $80 Million Common Stock Purchase Agreement With White Lion GBM Innovation Fund, With An Eye Towards Leveraging Innovate GBM's Non-Profit Ecosystem to Accelerate Glioblastoma Therapies

Apr 3, 2025, 7:30 AM EDT - 1 year ago

OSR Holdings, Inc. (NASDAQ: OSRH) Enters Into $80 Million Common Stock Purchase Agreement With White Lion GBM Innovation Fund, With An Eye Towards Leveraging Innovate GBM's Non-Profit Ecosystem to Accelerate Glioblastoma Therapies

Vaximm AG, an OSR Company, Announces Results from Phase 2a Trial of VXM01 and Avelumab Combination Therapy in Glioblastoma

Mar 26, 2025, 7:16 AM EDT - 1 year ago

Vaximm AG, an OSR Company, Announces Results from Phase 2a Trial of VXM01 and Avelumab Combination Therapy in Glioblastoma

OSR Holdings Appoints Dr. Constance Höfer as Chief Scientific Officer

Mar 25, 2025, 7:00 AM EDT - 1 year ago

OSR Holdings Appoints Dr. Constance Höfer as Chief Scientific Officer

OSR Holdings, Inc. and OSR Holdings Co., Ltd. Announce Completion of Business Combination

Feb 14, 2025, 6:10 PM EST - 1 year ago

OSR Holdings, Inc. and OSR Holdings Co., Ltd. Announce Completion of Business Combination

CelestialSurfing
CelestialSurfing Jul. 4 at 8:00 PM
$OSRH I’m still not fully convinced on this one. I put a good chunk of my portfolio into another stock I follow because new management turned around the company and put their money where their mouth is with: 1.) Affiliated partner renting out their datacenters, with compensation being way OTM warrants. (Reminds me of BCME deal) 2.) Open market insider purchases from ceo, board, and partners It’s interesting to me that there are zero open market purchases by insiders on OSRH. If this CVR deal is so legitimate? Why aren’t they loading up? Their ~400k salaries surely have room for some purchases
2 · Reply
Spiderman1979
Spiderman1979 Jul. 4 at 1:32 PM
$OSRH pretty darn, good news! Right now, I will take it.
1 · Reply
rodyar
rodyar Jul. 4 at 12:47 PM
$OSRH I hope the snowball is just about ready to start rolling down the mountain this month
1 · Reply
HarmonicHaven
HarmonicHaven Jul. 3 at 9:37 PM
$OSRH got fresh third-party coverage after Emerging Growth Research reaffirmed a Buy-Emerging rating and $10 PT. New visibility matters here — especially for a small-cap healthcare name that can move on coverage alone.
1 · Reply
GoldenGateGamma
GoldenGateGamma Jul. 3 at 9:22 PM
$OSRH got fresh third-party coverage after Emerging Growth Research reaffirmed a Buy-Emerging rating and $10 PT. New visibility matters here — especially for a small-cap healthcare name that can move on coverage alone.
0 · Reply
rodyar
rodyar Jul. 3 at 3:50 PM
$OSRH risk versus reward. Nobody ever knows exactly what a stock is going to do so when you go in and buy it, you weigh the potential versus risking everything. With the CVR on the table that makes it worth the risk in my opinion for new investors. Obviously the company feels pretty confident what they’re going to do over the next year and by this time next year, we will either be really happy or not so happy.
1 · Reply
Panda0820
Panda0820 Jul. 3 at 3:31 PM
$OSRH Adding and Adding
2 · Reply
Safey_8
Safey_8 Jul. 3 at 3:12 PM
$OSRH still
0 · Reply
KeepItRealistic
KeepItRealistic Jul. 3 at 2:08 PM
$OSRH what is stopping BCME investors from buying up a good chunk of the remaining float here estimated at around 20m ? A shareholder loyalty program 🤷🏻‍♂️ Who needs these retarded fliptards when we have BCME ! Smart loyal shareholders will just ride on BCME’s coattails ! I am excited to that possibility
1 · Reply
KeepItRealistic
KeepItRealistic Jul. 3 at 3:04 AM
$OSRH to new long investors buy 10k shares and HOLD for 1 year and turn 10k shares to 60k shares. • Details: One non-transferable CVR per share held as of the record date (targeted for July 31, 2026). Subject to legal counsel approval. • Tiered Rewards: The tiered reward structure only has to be at or above the specified price level on the 3, 6, 9, or 12 month observation date • ≥ $2.00 for 3 months → 0.5 additional shares • ≥ $3.00 for 6 months → 1.0 additional shares • ≥ $4.00 for 9 months → 1.5 additional shares • ≥ $5.00 for 12 months → 2.0 additional shares • Maximum upside: A shareholder holding through all tiers could receive 5 additional shares per original share, effectively turning 1 share into 6.
0 · Reply
KeepItRealistic
KeepItRealistic Jul. 3 at 1:31 AM
$OSRH next is the company filing the definitive CVR agreement with the SEC.
0 · Reply
Bearbull_Baggins
Bearbull_Baggins Jul. 3 at 1:06 AM
$OSRH Well well well....👀
1 · Reply
Bearbull_Baggins
Bearbull_Baggins Jul. 3 at 12:42 AM
$OSRH I know everyone has dilution concerns. But I am still not convinced that is what is currently going on. I have been here since last year and the price action has been like this. When they disclose their dilution, it is not enough to make sense of what we see, and it happens on days where ANY company would utilize such an option (high volume bullish days). I keep telling people that the structure of White Lion ELOC is essentially useless on these slow drawn out bearish trends. I am not naive and i am aware i could be wrong, but i am not saying this to pump or to be in denial of anything. Draw your own conclusions, but give it some thought first.
2 · Reply
KeepItRealistic
KeepItRealistic Jul. 3 at 12:24 AM
$OSRH AH close .33 👇 More real investors coming as the word gets out on the 6x share Loyalty program opportunity
0 · Reply
KeepItRealistic
KeepItRealistic Jul. 2 at 10:25 PM
$OSRH 6x your shares just for being patient … read PR below for exciting details … Company also has $15 million in funding at $10 a share in October (in 3 months)
0 · Reply
OSR_Health_IR
OSR_Health_IR Jul. 2 at 10:21 PM
$OSRH https://www.accessnewswire.com/newsroom/en/biotechnology/correction-from-source-emerging-growth-research-issues-flash-report-on-osr-health-inc-1186012
0 · Reply
Tommyj1014
Tommyj1014 Jul. 2 at 9:11 PM
$OSRH CORRECTION FROM SOURCE: Emerging Growth Research Issues Flash Report on OSR Health, Inc., Reaffirms Buy-Emerging Rating and $10.00 Price Target https://www.webullapp.com/news-detail/15158849711342592?__app_cfg__=%7B%22supportTheme%22%3Atrue%7D&sourcePage=QuotesFragment&tickerId=950985377&audioNewsPlayedDuration=&theme=1&color=2&hl=en&android_sdk_int=36&canary-version=&_v=1&sp=1&statusBarHeightV2=44&isLite=false&wbFontSetting=standard&wbFontUnit=29&wbFontSize=29&isSubsNews=false
0 · Reply
KeepItRealistic
KeepItRealistic Jul. 2 at 8:32 PM
$OSRH closed .3206 Enjoy the long weekend with family ! Maybe we finally get some solid news on Monday !
1 · Reply
KeepItRealistic
KeepItRealistic Jul. 2 at 7:35 PM
$OSRH who is going to take out that monkey at .3420 …
0 · Reply
KeepItRealistic
KeepItRealistic Jul. 2 at 7:19 PM
$OSRH investors are catching on
0 · Reply
TySpy
TySpy Jul. 2 at 7:18 PM
$OSRH No way! We going places today???? 😃
0 · Reply
KeepItRealistic
KeepItRealistic Jul. 2 at 7:11 PM
$OSRH huge difference ! “The tiered reward structure only has to be at or above the specified price level on the 3, 6, 9, or 12 month observation date. It was previously mentioned that the pricing needed to be sustained over that time period.” https://ca.finance.yahoo.com/news/correction-source-emerging-growth-research-170500642.html
0 · Reply